These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12620695)

  • 1. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.
    Aurigemma GP; Devereux RB; Wachtell K; Palmieri V; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    Am J Hypertens; 2003 Mar; 16(3):180-6. PubMed ID: 12620695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
    Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
    Mancusi C; Gerdts E; De Simone G; Abdelhai YM; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2014 Aug; 23(4):206-12. PubMed ID: 24564262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
    Biederman RW; Doyle M; Young AA; Devereux RB; Kortright E; Perry G; Bella JN; Oparil S; Calhoun D; Pohost GM; Dell'Italia LJ
    Hypertension; 2008 Aug; 52(2):279-86. PubMed ID: 18606908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Gerdts E; Okin PM; de Simone G; Cramariuc D; Wachtell K; Boman K; Devereux RB
    Hypertension; 2008 Apr; 51(4):1109-14. PubMed ID: 18259011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
    Bella JN; Palmieri V; Wachtell K; Liu JE; Gerdts E; Nieminen MS; Koren MJ; Zabalgoitia M; Wright JT; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):411-6. PubMed ID: 15042116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.
    Olsen MH; Wachtell K; Borch-Johnsen K; Okin PM; Kjeldsen SE; Dahlöf B; Devereux RB; Ibsen H
    J Hum Hypertens; 2002 Aug; 16(8):591-5. PubMed ID: 12149666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
    J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
    Gerdts E; Franklin S; Rieck A; Papademetriou V; Wachtell K; Nieminen M; Dahlöf B; Devereux RB
    Blood Press; 2009; 18(4):180-6. PubMed ID: 19562573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
    Wachtell K; Palmieri V; Olsen MH; Gerdts E; Papademetriou V; Nieminen MS; Smith G; Dahlöf B; Aurigemma GP; Devereux RB
    Circulation; 2002 Jul; 106(2):227-32. PubMed ID: 12105163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
    Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
    Devereux RB; Roman MJ; Palmieri V; Okin PM; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Dahlöf B
    J Hypertens; 2000 Aug; 18(8):1129-38. PubMed ID: 10954006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.